Pharmaceuticals, Biotechnology and Life Sciences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical…
WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies…
Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending…
TUSTIN, Calif., March 06, 2023 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization…
DUBLIN, Ireland and BRIDGEWATER. N.J., March 06, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”)…
PALO ALTO, Calif., March 06, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused…
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 and Report Interim data in…
First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut…
Q4 2022 revenue $21.2 million and FY 2022 revenue $74.9 millionFY 2023 revenue guidance range $95-98 million MARLBOROUGH, Mass., March…
– Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities – –…